154 related articles for article (PubMed ID: 37973906)
1. Genomic Landscape of Pulmonary Sarcomatoid Carcinoma.
Kwon HJ; Lee S; Han YB; Lee J; Kwon S; Kim H; Chung JH
Cancer Res Treat; 2024 Apr; 56(2):442-454. PubMed ID: 37973906
[TBL] [Abstract][Full Text] [Related]
2. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
[TBL] [Abstract][Full Text] [Related]
3. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
Fischer A; Bankel L; Hiltbrunner S; Rechsteiner M; Rüschoff JH; Rushing EJ; Britschgi C; Curioni-Fontecedro A
Target Oncol; 2022 Nov; 17(6):683-694. PubMed ID: 36136211
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
[TBL] [Abstract][Full Text] [Related]
5. Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas.
Qin J; Chen B; Li C; Yan J; Lu H
Cancer Genet; 2021 Jan; 250-251():12-19. PubMed ID: 33217678
[TBL] [Abstract][Full Text] [Related]
6. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
[TBL] [Abstract][Full Text] [Related]
7. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523
[TBL] [Abstract][Full Text] [Related]
8. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
Zhou F; Huang Y; Cai W; Li J; Su C; Ren S; Wu C; Zhou C
Lung Cancer; 2021 Mar; 153():66-72. PubMed ID: 33454519
[TBL] [Abstract][Full Text] [Related]
9. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
[TBL] [Abstract][Full Text] [Related]
12. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8
Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S
Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068
[TBL] [Abstract][Full Text] [Related]
13. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
14. Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies.
Stephan-Falkenau S; Streubel A; Mairinger T; Blum TG; Kollmeier J; Mairinger FD; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445733
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Pathological Characteristics of
Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
[No Abstract] [Full Text] [Related]
16. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
Jain E; Sharma S; Aggarwal A; Bhardwaj N; Dewan A; Kumar A; Jain D; Bhattacharya M; Saurav GK; Kini L; Mohanty SK
Pathol Res Pract; 2021 Dec; 228():153497. PubMed ID: 34053784
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
19. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
[TBL] [Abstract][Full Text] [Related]
20. Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies.
Shen E; Xiu J; Bentley R; López GY; Walsh KM
Clin Lung Cancer; 2020 Nov; 21(6):e523-e527. PubMed ID: 32414627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]